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Available online 29 January 2016Iron is an indispensable micronutrient that regulates many aspects of cell function, including growth and prolif-
eration. These processes are critically dependent upon signalling via the mammalian or mechanistic target of
rapamycin complex 1 (mTORC1). Herein, we test whether iron depletion induced by cell incubation with the
iron chelator, deferoxamine (DFO), mediates its effects on cell growth through mTORC1-directed signalling
and protein synthesis. We have used Caco-2 cells, a well-established in vitromodel of human intestinal epithelia.
Iron depletion increased expression of iron-regulated proteins (TfR, transferrin receptor and DMT1, divalent
metal transporter, as predicted, but it also promoted a marked reduction in growth and proliferation of Caco-2
cells. This was strongly associated with suppressed mTORC1 signalling, as judged by reduced phosphorylation
of mTOR substrates, S6K1 and 4E-BP1, and diminished protein synthesis. The reduction in mTORC1 signalling
was tightly coupledwith increased expression and accumulation of REDD1 (regulated inDNAdamage and devel-
opment 1) and reduced phosphorylation of Akt and TSC2. The increase inREDD1 abundancewas rapidly reversed
upon iron repletion of cells but was also attenuated by inhibitors of gene transcription, protein phosphatase 2A
(PP2A) and by REDD1 siRNA — strategies that also antagonised the loss in mTORC1 signalling associated with
iron depletion. Our ﬁndings implicate REDD1 and PP2A as crucial regulators of mTORC1 activity in iron-
depleted cells and indicate that their modulation may help mitigate atrophy of the intestinal mucosa that may
occur in response to iron deﬁciency.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Deferoxamine1. Introduction
Iron is an essentialmicronutrient that plays a vital role in the control
of multiple cellular processes including the transfer of electrons within
the mitochondrial respiratory chain and the expression of key genes
that inﬂuence cellular metabolism, growth and differentiation. At the
systemic level, iron is essential for the inter-organ transport and tissue
uptake of oxygen by virtue of its crucial role in haemoglobin and
myoglobin biology. The physiology and control of such processes is
thus likely to be affected by changes in iron homeostasis, which, in the
absence of a regulated excretory pathway, is critically dependent upon
dietary iron intake and mechanisms controlling iron storage and use
in tissues such as liver, muscle and erythrocytes [1]. Whilst excess iron
accumulation is a feature of genetic disorders such as hereditaryin DNA damage and develop-
, eIF4E-binding protein 1; HIF,
IRS, insulin receptor substrate;
tein S6 kinase 1; S6, ribosomal
sferrin receptor.
d Immunology, Sir James Black
dee DD1 5EH, UK.
l).
. This is an open access article underhaemochromatosis, a far more prevalent problem with respect to iron
balance is iron deﬁciency, which affects nearly 30% of the global popula-
tion [2].
Growth ofmammalian cells is sensitive to iron availability [3–5] and,
as such, this may be an important determinant of the proliferative
capacity of cells that normally “turn-over” very rapidly, such as the ab-
sorptive epithelial cells lining the intestinal mucosa. A key metabolic
pathway which has been implicated strongly as a regulator of cell
growth and proliferation is that involving themammalian or mechanis-
tic target of rapamycin (mTOR) [6]. Reduced mTOR signalling has been
reported in cells and tissues of animals rendered iron deﬁcient [17],
although the mechanism(s) underlying these observations remains
unclear.
mTOR is an essential component of two separate protein signalling
complexes, known as mTORC1 andmTORC2, which, owing to their dis-
tinct biochemical composition [6–8], display differential sensitivity to
the immunosuppressant rapamycin [6] that only targetsmTORC1. Func-
tionally, mTORC2 serves as one of the two upstream kinases involved in
the insulin-dependent activation of the serine/threonine kinase PKB
(aka Akt). In contrast, mTORC1 integrates mitogenic and nutrient
signals to ensure that growth and proliferation of cells only occurs
under nutritionally favourable conditions — a role made possible bythe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ditions (thus promoting phosphorylation of downstreameffectors, such
as p70S6 kinase 1 (S6K1) and 4E-BP1 that play important roles in the
regulation of protein synthesis [9]) but is dramatically repressed upon
AA withdrawal [6]. Activation of mTORC1 is crucially dependent upon
a small G-protein called Rheb,which in its GTP-loaded “on” form is a po-
tent activator of mTORC1 [10]. The relative amounts of Rheb in the GTP
“on” or GDP “off” form depend upon its intrinsic GTPase activity, which
is a target for the GTPase-activating protein (GAP) activity of the tuber-
ous sclerosis complex (TSC1/2) [10]. TSC2 is a physiological substrate for
PKB/Akt, whose activation by insulin and growth factors induces phos-
phorylation of TSC2 and inhibition of its GAP activity, which then aids ac-
cumulation of active Rheb and a consequential increase in mTORC1
activity [11]. Activation of mTORC1 is also dependent on small G proteins
of the Rag family, which operate as heterodimers (RagA or RagB
with RagC or RagD) to promote redistribution of mTORC1 to lysosomal
membranes in response to AA provision [12]. Rags are tethered to
the lysosomal surface by interactionswith two heteromeric protein com-
plexes; (i) the Ragulator (Rag regulator) complex [12] and (ii) the vacu-
olar H+-ATPase resident in the lysosomalmembrane [13]. AA-dependent
modulation of these interactions appears to facilitate binding of mTORC1
to Rag complexes, placing it in close proximity to its activator Rheb [13].
In contrast, inactivation of mTOR may, in part, be driven by regulat-
ing the localisation of the TSC complex. Insulin and AAs have recently
been shown to promote dissociation of TSC1/TSC2 from lysosomal
membranes, whereas the absence of these stimuli induces greater lyso-
somal association of the complexwhere it facilitates conversion of Rheb
to its inactive GDP-form and thus a reduction in mTOR activity [14,15].
mTORC1 can also be negatively regulated by REDD1 (regulated in
DNA damage and development 1), a small 25 kDa protein whose
expression is induced in response to environmental stresses, such as
hypoxia [16]. Precisely how REDD1 inhibits mTORC1 activity is unclear
although it has been suggested to sequester 14-3-3 proteins away
from TSC2, which may then permit TSC2 to target its GAP activity
towards Rheb [17]. More recent work has shown that ectopic over-
expression of REDD1 in HEK293 cells induces association of protein
phosphatase 2A (PP2A)with Akt causing dephosphorylation and inacti-
vation of the kinase on one of its key regulatory sites (Thr308) that,
in turn, reduces its capacity to phosphorylate and inhibit TSC2 and con-
sequently promote downstream activation of Rheb [18]. However, it re-
mains unclear if such amechanismmay account for the reduction in Akt
and mTORC1 signalling observed in cells and tissues of animals ren-
dered iron deﬁcient [17]. In this study we have investigated the effect
of iron deﬁciency on the growth and proliferative potential of intestinal
epithelial cells. We show that iron depletion induced in human intesti-
nal Caco-2 cells by treatment with the iron chelator deferoxamine
(DFO) results in REDD1 induction and that this is associated with not
only a fall in Akt and TSC2 phosphorylation, but reduced mTORC1 sig-
nalling and a marked suppression in protein synthesis and cellular pro-
liferation. Strikingly, the increase in REDD1 expression initiated by DFO
treatment can be attenuated by PP2A inhibition and this is associated
with retention of mTORC1 signalling in otherwise iron-deﬁcient cells.
Our work identiﬁes REDD1 and PP2A as potential therapeutic targets
whosemodulationmay help restrain loss inmTORC1 activity and there-
by potentially limit intestinal mucosal atrophy associated with chronic
or recurrent iron deﬁciency disorders [19,20].
2. Materials and methods
2.1. Materials
Dulbecco's Modiﬁed Eagle Medium (DMEM), penicillin–streptomy-
cin, MEM Non-Essential AAs Solution, amphotericin B and Trypsin–
EDTA were purchased from Life Technologies (Paisley, UK). Heat
inactivated foetal bovine serum (FBS)was bought fromThermo Scientiﬁc
(Waltham, MA, USA). Sodium pyruvate, Earle's Balanced Salt Solution(EBSS), gelatin from cold water ﬁsh skin (FSG), TriReagent®, SYBR®
Green kit, human holo-Transferrin and all protease inhibitors were pur-
chased from Sigma-Aldrich (Poole, UK). Puromycin and cycloheximide
was purchased from Abcam (Cambridge, UK). Protein Assay Dye
Reagent Concentrate was from Bio-Rad (Hemel Hempstead, UK).
GoTaq® DNA Polymerase, deoxyribonucleotide phosphates (dNTPs)
and Moloney Murine Leukaemia Virus (M-MLV) reverse transcriptase
were fromPromega (Southampton, UK). Deferoxamine (DFO)mesylate
salt and polyvinylidene diﬂuoride (PVDF) membranes were purchased
from Merck Millipore (Darmstadt, Germany). X-ray ﬁlm was sourced
from Konica Minolta (Tokyo, Japan). The transcription inhibitor actino-
mycin D was purchased from Tocris (Bristol, UK) and the proteasome
inhibitor MG132 was from Selleck Chemicals (Houston, USA). Antibod-
ies to DMT1, TfR and PP2A-α (Tyr 307) were purchased from Abcam
(Cambridge, UK). Actin and GAPDH antibodies were from Sigma
(Poole, UK). The antibody to HIF-1α was purchased from BD Biosci-
ences (Oxford, UK), the REDD1 antibody fromProteintech (Manchester,
UK), the puromycin antibody from Kerafast (Boston, USA) and native
PP2A from the Division of Signal Transduction Therapy (DSTT; University
of Dundee, UK). All other antibodies, including horse-radish peroxidise-
conjugated secondary antibodies (mouse and rabbit) and that to cleaved
caspase 3, were purchased from New England Biolabs (Hitchin, UK). All
qPCR primers were synthesised by the Oligonucleotide Synthesis Service
(University of Dundee).
2.2. Cell culture
Caco-2 cells were cultured in Dulbecco's Modiﬁed Eagle Medium
(DMEM) containing 1 mM sodium pyruvate, 1% (v/v) penicillin–
streptomycin (ﬁnal concentration 100 μg/ml penicillin, 100 μg/ml
streptomycin), 1% (v/v) non-essential AAs, 10% (v/v) heat inactivated
foetal bovine serum (FBS) and 250 ng/ml amphotericin B. Medium
was changed every two days and cells were maintained at 37 °C in
10% CO2. For experimentation, cells were seeded at a density of
2.2 × 104 cells/cm2 on 6-well plates and reached conﬂuence by day 3.
Caco-2 cells were depleted of iron by incubation in media supplement-
ed with 10% FBS and the iron chelator deferoxamine (DFO) [5] for
periods and at concentrations indicated in the text and ﬁgure legends.
2.3. Protein extraction, immunoprecipitation and immunoblotting
Immunoblot analysis was carried out as previously described [21].
Following cell treatment, Caco-2 cells were washed with ice cold PBS
and then immediately lysed in ice cold lysis buffer [50 mM Tris/HCl
pH 7.4, 0.27 M sucrose, 1 mM sodium orthovanadate, 1 mM EDTA,
1 mM EGTA, 10 mM sodium 2-glycerophosphate, 50 mM sodium ﬂuo-
ride, 5 mM sodium pyrophosphate, 1% (w/v) Triton X-100, 0.1% (v/v)
2-mercaptoethanol and protease inhibitor (one tablet/50 ml)]. Cell de-
bris was removed from crude cell lysates by centrifugation at 3000 g
for 10 min at 4 °C, and the resulting supernatant used for Western
blot analysis. In some experiments, following treatment with DFO,
Caco-2 cells were lysed as described above. PP2Ac was immuno-
precipitated from 0.5 mg of protein lysate using an antibody against
the C-terminal domain of PP2Ac. Resulting immunocomplexes were
captured by incubationwith protein-A-sepharose beads and solubilised
in Laemmli sample buffer prior to immunoblotting using an antibody
targeting REDD1 or PP2Ac. Proteins from cell lysates (30 μg) or immu-
noprecipitates were subjected to SDS-polyacrylamide gel electrophore-
sis and immunoblotted using primary antibodies to proteins of interest
as previously described [21]. Resulting band intensities were quantiﬁed
using ImageJ software (National Institutes of Health, Bethesda, MD).
2.4. RNA extraction and qPCR analysis
Total RNA was extracted from Caco-2 cells using Tri-Reagent® ac-
cording to manufacturer's instructions (Sigma-Aldrich). Quantitative
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tem (Applied Biosystems), SYBR Green JumpStart Taq Ready Mix
(Sigma-Aldrich) and primers targeting 18S rRNA (18S ribosomal ribo-
nucleic acid) as a control. The human sequences for the primers used
were as follows: DMT1 forward, 5′-GACTCGCTCTATTGCCATCATCC-3′;
DMT1 reverse, 5′-ATCCGCCAGCCTAGTCCATTG-3′; TfR forward, 5′-
CAATACAGAGCAGACATAAAGGAA-3′; TfR reverse, 5′-CTGGAAGTAGCA
CGGAAGAA-3′; REDD1 forward, 5′-CTTTGGGACCGCTTCTCGTC-3′;
REDD1 reverse, 5′-GGTAAGCCGTGTCTTCCTCCG-3′; 18S rRNA forward,
5′-CAGCCACCCGAGATTGAGCA-3′; 18S rRNA reverse, 5′-TAGTAGCGAC
GGGCGGTGTG -3′. qPCR ampliﬁcationwas performedwith an initial de-
naturation at 95 °C for 10 min followed by 40 cycles of denaturation at
95 °C for 15 s, annealing at 55 °C for 15 s, and extension at 68 °C for
1 min. The ratio of mRNA of interest to 18S rRNA mRNA expression
was calculated using a mathematical model previously described [22].
2.5. Amino acid analysis by HPLC
Caco-2 cells were lysed in water and mixed with triﬂuoroacetic acid
and methanol (1∶10). Supernatants were dried off in a rotary evapora-
tor at 46 °C. Samples were suspended in sodium acetate, Methanol, TEA
(2∶2:1), methanol, H2O, TEA, PITC (7∶1:1∶1) andmethanol (100%)with
drying steps between each step. The resulting phenylthiocarbamyl
peptides were separated by a Hewlett Packard 1050 HPLC systemFig. 1. Effects of DFO-induced iron depletion upon cellular proliferation in Caco-2 cells. (A) Caco
plate cells were treated with or without 100 μMDFO or 100 μM iron-loaded DFO for up to 5 da
every 24 h during the 5 day treatment period. Point values on the line graphs for each treatme
analytical time point was lysed for analysis of cell protein. The asterisk represents a signiﬁcant
mean uptake ± SEM from three experiments. (C) Caco-2 cells were incubatedwith 100 μMDFO
antibodies targeting cleaved caspase 3 and α-tubulin (as a gel loading control). The ratio of cle(Minnesota, USA) with post-column UV detection (254 nm). HPLC
traces were analysed using the Clarity Lite software.2.6. Protein synthesis
Protein synthesis wasmeasured as described by Goodman et al. [23]
by assaying the incorporation of puromycin into newly synthesised
peptides. Brieﬂy, cells were pretreated as described in the ﬁgure legend
withDFO, iron-loadedDFO or cycloheximide (50 μg/ml) prior to incuba-
tion in the absence or presence of 1 μM puromycin for 30 min. At the
end of this period cells were lysed and lysates subjected to SDS-PAGE
and immunoblotting of PVDF membranes carried out overnight at 4 °C
with a mouse monoclonal anti-puromycin antibody (1 μg/ml in TBST
with 5% w/v non-fat dry milk) followed by incubation with goat anti-
mouse HRP secondary antibody.2.7. Statistical analysis
Statistical analysis was performed using GraphPad Prism. Data are
presented as mean ± standard error of mean (SEM) with quantitative
and statistical assessments being derived from aminimum of three rep-
licates per group. Values used to normalise results in each experiment
were excluded from statistical analysis, which involved analysis of-2 cells were seeded at a density of 200,000 cells/cm2. Following adherence to the culture
ys with media and treatment agent being refreshed every 24 h. Cell number was assessed
nt represent mean ± SEM from three experiments. (B) Cells were treated in (A) and each
change (p b 0.05) from the control bar value on each of the treatment days. Bars represent
24 h (n= 3) or vehicle solution (n= 3) prior to cell lysis and immunoblot analysis using
aved caspase 3 to α-tubulin is indicated above each lane.
Fig. 2. Iron depletion suppresses mTOR signalling and enhancesmRNA and protein expression of TfR and DMT-1. Caco-2 cells were incubatedwith deferoxamine (DFO) at concentrations
indicated in (A) for 16 h orwith 100 μMDFO for incubation periods as indicated in (B) prior to cell lysis and immunoblot analysis using antibodies targeting p70S6 Kinase Thr389, S6 Ser240/244,
4E-BP1 Ser65, 4E-BP1 and S6. Immunoblot data was quantiﬁed using ImageJ and presented as mean ± SEM from ﬁve independent experiments. Asterisks denote statistical signiﬁcance
between the indicated values (*p b 0.05). (C) Total RNA was extracted from Caco-2 cells that had been treated with or without 100 μM DFO for 16 h and DMT1 and TfR mRNA expression
assessed using real-time PCR by normalising to 18S rRNA. Lower panel shows the effect of DFO treatment in these cells upon DMT1 and TfR protein abundance.
Fig. 3. Effects of iron depletion upon amino acid-dependent activation of mTORC1 signalling and intracellular amino acid abundance in Caco-2 cells. (A) Caco-2 cells were incubated in
DMEM/10% FBS, in the absence or presence of 100 μM deferoxamine (DFO) or 100 μM iron loaded DFO for 16 h prior to being incubated in Hepes buffered saline (HBS)/10% FBS
containing or lacking amino acids (AA) for a further 6 h. In some experiments, cells that had been incubated in AA-depleted buffer were subsequently “refed”with HBS/FBS containing 1x
physiological AA mix for 15 min. At the end of these incubations, cells were lysed and lysates used for immunoblotting with antibodies against p70S6 Kinase Thr389 and native p70S6
Kinase. Immunoblots were quantiﬁed and data presented as mean ± SEM from three experiments. Asterisks indicate a signiﬁcant change (p b 0.05) between indicated values. (B) Cells
were incubated in the absence or presence of 100 μM DFO for 16 h before lysis in water and analyses of AA content by HPLC. Values presented are the mean ± SEM from three
independent experiments.
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isons. Signiﬁcance was set at a P value of b0.05.
3. Results
3.1. Effects of iron deﬁciency on proliferation of Caco-2 cells
Monolayers of Caco-2 cells were iron depleted by exposure to
100 μMDFO (an iron-chelator). Fig. 1A shows that, compared to control
cells or cells incubated with iron-loaded DFO, sustained exposure of
Caco-2 cells to DFO effectively suppressed cell proliferation over the
treatment period with the chelator. In line with this observation, whilst
total cell protein increased in control cells or those incubatedwith iron-
loaded DFO this was not observed in cells that were iron-depleted with
DFO (Fig. 1B). Indeed, exposure of cells to DFO for periods greater than
3 days was associated with a reduction in total cell protein which most
likely arises as a consequence of iron depletion initiating an increase
in cell death. The presence of cleaved caspase 3 (a well-established ap-
optotic marker) in cells that had been treated with DFO for 24 h is en-
tirely consistent with this latter proposition (Fig. 1C).
3.2. Iron deﬁciency downregulates mTORC1-directed signalling
The mTORC1/S6K1 signalling axis exerts a positive inﬂuence on cell
growth and protein synthesis. Consequently, impaired activation of this
signalling pathway in iron depleted cells would be expected to impact
negatively on these cellular processes. In an attempt to understand
the impact that iron deﬁciency may have upon mTORC1 signalling,
Caco-2 cells maintained in DMEM containing amino acids and FBS
were incubated with increasing concentrations of DFO (0–100 μM) for
16 h prior to assessing the phosphorylation status of S6K1, S6 and 4E-
BP1. Fig. 2A shows that in the absence of DFO treatment we observed
phosphorylation of S6K1 and 4E-BP1 on their respective mTORC1 regu-
lated sites (Thr389 and Ser65) and that of ribosomal S6 on Ser240/244,Fig. 4. Effects of DFO-induced iron depletion on Akt and mTORC1 signalling in Caco-2 cells. Cac
16 h. (B) Alternatively, having been incubated with DFO for this period they were subsequen
these incubations cells were lysed and lysates immunoblotted with antibodies against (A) A
(A) was quantiﬁed and presented as the mean ± SEM from six independent experiments. Astwhich represent downstream target sites for S6K1. Phosphorylation of
all three proteins was reduced by cell treatment with DFO in a dose-
dependent manner with that of S6K1 and S6 being suppressed by up
to ~80% in response to a 100 μMDFOdose. At this dose, phosphorylation
of S6K1 and S6 were maximally reduced by 16 h of cell treatment with
DFO (Fig. 2B). It is noteworthy that multi-site 4E-BP1 phosphorylation
normally results in the appearance of a diffuse immunoreactive protein
band for total 4E-BP1 as shown in the control lane, which stems from
the differential gel shifts associated with varying 4E-BP1 phosphoryla-
tion. However, consistent with its dephosphorylation in iron-depleted
cells this 4E-BP1 band becomes sharper with increasing concentrations
of DFO. It is also important to stress that the reduced phosphorylation of
S6K1, S6 or 4E-BP1 induced by DFO treatment is not a consequence
of changes in the overall expression of these proteins, which were not
signiﬁcantly affected by DFO.
The reduction inmTORC1 signalling seenwith the DFO in our cells is
within the dose range and incubation times previously reported by
other investigators exploring effects of iron depletion on, for example,
cellular signalling and growth arrest [5,24]. However, to validate that
DFO does indeed reduce iron availability within our cells we monitored
the abundance of the divalent metal transporter-1 (DMT-1) and the
transferrin receptor (TfR), whose expression is known to be upregulat-
ed in cells and tissues upon iron depletion [25–27]. Fig. 2C shows
that Caco-2 cells incubated with DFO (100 μM, 16 h) exhibit a 2.3 and
3-fold increase in DMT-1 and TfR mRNA expression respectively,
which is also associated with increased cellular abundance of both pro-
teins (Fig. 2C, lower panel).
3.3. Effects of DFO treatment on AA-induced activation of S6K1 and intra-
cellular AA content
In addition to insulin and growth factors, mTORC1 activation is cru-
cially dependent upon AA availability [6]. Consequently, it is plausible
that the loss in S6K1, 4E-BP1 and S6 phosphorylation induced by DFOo-2 cells were incubated with deferoxamine (DFO) at concentrations indicated in (A) for
tly resupplemented with iron using human 10 μM holo-Transferrin for 6 h. At the end of
kt Thr308, Akt Ser473 and native Akt or (B) proteins indicated. The Akt Thr308 signal in
erisks denote statistical signiﬁcance between the indicated values (*p b 0.05).
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capacity for inducing stimulation of the mTORC1/S6K1 signalling axis.
To test this proposition, Caco-2 cells that had undergone prior incuba-
tion with media containing serum and DFO or the vehicle solution
alonewere AA deprived for 6 h or having been AAdeprivedwere subse-
quently held inmedia containing serum and AAs for 15min. Analysis of
S6K1 phosphorylation revealed that, in the absence of DFO treatment,
depriving cells of AA for 6 h reduced S6K1 phosphorylation by over
80% (Fig. 3A, compare lane 1 and 2), whereas acute AA refeeding after
a period of AA starvation reinstated S6K1 phosphorylation to a level
comparable if not greater than that seen in control cells (compare lane
3 with lanes 1 and 2). Consistent with the data presented in Fig. 2A,
DFO treatment reduced S6K1 phosphorylation by ~60%, which was re-
duced further (by ~20%)when iron-depleted cellswere also AAdeprived
(Fig. 3A, lanes 4 and 5). Intriguingly, refeeding DFO-treated cells with
AA could only partially recover the deﬁcit in S6K1 phosphorylation
(compare lanes 3 and6) suggesting thatwhilst AA availabilitywas an im-
portant determinant of S6K1 activation, iron depletion is associatedwith
anabolic resistance in terms of the ability of AAs to fully activatemTORC1
signalling. It is noteworthy that HPLC analysis of intracellular AA contentFig. 5. Effects of iron depletion/resupplementation uponREDD1mRNA and protein expression in
16 h or (B) at the concentrations indicated. In some experiments (C), cells treated with DFO we
the end of these treatment incubations total mRNA was extracted from Caco-2 cells and (A) RE
lysed and lysates immunblotted using antibodies against REDD1, p70S6 Kinase Thr389, S6 Ser24
REDD1 and S6 Ser240/244 phosphorylation is shown above blots and data expressed as mea
(p b 0.05) between indicated values.especially of those AAs (e.g. BCAA) that convey a potent stimulatory ef-
fect onmTORC1 signalling [6] were found to be unaffected by DFO treat-
ment (Fig. 3B) thus excluding the possibility that reduced mTORC1
signalling by AAs was a consequence of disturbances in the intracellular
AA pool.
As an additional control, we also monitored the effects of AA
withdrawal/refeeding on S6K1 phosphorylation in cells incubated with
DFO that had been preloaded with iron so that the chelator would not
induce iron depletion when applied onto cells. Fig. 3A shows that this
treatment had no impact upon S6K1 phosphorylation (compare lanes 1
and 7) and that the response to AA withdrawal/refeeding was similar
to that seen in non-DFO treated cells (compare lanes 2 and 3 with lanes
8 and 9); i.e. the effects were due to iron depletion rather than any off-
target effect of DFO.
3.4. Cellular iron depletion impairs Akt-mediated signalling
In an attempt to understand how iron depletion reduces mTORC1
signalling we subsequently explored the effect of DFO treatment
on Akt signalling, which conveys a positive stimulatory input intoCaco-2 cells. Caco-2 cellswere incubated in the absence or presence of (A) 100 μMDFO for
re subjected to iron resupplementation using 10 μMholo-Transferrin over a 6 h period. At
DD1 mRNA abundance quantiﬁed relative to 18S rRNA by qPCR. Alternatively, cells were
0/244 and GAPDH, which served as a gel loading control. Corresponding quantiﬁcation for
n ± SEM from at least three experiments. The asterisk represents a signiﬁcant change
418 A. Watson et al. / Cellular Signalling 28 (2016) 412–424mTORC1 signalling. Fig. 4A shows that DFO induces a dose-dependent
reduction in AktThr308 phosphorylation, which fell signiﬁcantly over a
16 h period by up to 80% in cells treated with 100 μM DFO. Strikingly,Fig. 6. Effects of DFO and okadaic acid on PP2A tyrosine phosphorylation, REDD1 expression an
media supplementedwith DFO (100 μM) for 16 h prior to immunoprecipitation of PP2Ac and im
the indicated DFO concentrations for 16 h or with 100 μM DFO for times indicated after which
native PP2Ac. (C) Cellswere incubatedwith vehicle or 100 μMDFO for 16h orwith okadaic acid
lysed and immunoblottedwith antibodies against AktThr308 or native Akt. (D) Caco-2 cells were
DFO for 16h resupplementedwith humanholo-Transferrin for a further 6 h. In some experimen
100 nM) for the penultimate 2 h period of treatmentwithDFO or 10 μMholo-Transferrin. At the
qPCR analysis (upper panel) or lysed and lysates immunoblotted with antibodies against RE
mean ± SEM from at least three experiments. Immunoblots (B, C and D) were quantiﬁed u
experiments. The asterisk denotes statistical signiﬁcance between the indicated values (*p b 0
were and lysates immunoblotted with antibodies to the proteins shown.we did not observe any detectable changes in AktSer473 phosphoryla-
tion over the DFO dose range used in these studies. Since full activation
of the kinase is dependent on phosphorylation of both Akt regulatorydmTORC1 signalling in Caco-2 cells. (A) Caco-2 cells were incubated with DMEM/10% FBS
munoblottingwith antibodies to REDD1 or PP2Ac. (B) Cells were incubated as in (A) but at
cells were lysed and immunoblotted with antibodies against phospho-Tyr307 of PP2Ac or
(OKA, 100 nM) for thepenultimate 2 h period of treatmentwithDFO afterwhich cellswere
incubated in the absence or presence of 100 μMDFO for 16 h, or having been treatedwith
ts, cells treatedwithDFO andholo-Transferrinwere also incubatedwith okadaic acid (OKA,
end of these incubations cellswere either prepared for analysis of REDD1mRNA content by
DD1 and S6 Ser240/244. Analysis of REDD1 mRNA and protein abundance is presented as
sing ImageJ and data presented are the mean ± SEM from three or four independent
.05). (E) Cells were treated as in (D) with DFO and okadaic acid at the end of which they
419A. Watson et al. / Cellular Signalling 28 (2016) 412–424sites [28], we postulated that loss of Thr308 phosphorylation would re-
duce Akt signalling capacity. In line with this idea, Fig. 4B shows that
phosphorylation of TSC2 on Ser939 (a physiological downstreamAkt tar-
get site) was notably reduced in DFO-treated cells along with reduced
S6K1 and S6 phosphorylation. Resupplementation of iron-depleted
cells with iron saturated holo-transferrin for 6 h not only reinstated
AktThr308 and TSC2Ser939 phosphorylation, but also led to an attendant
increase in S6K1 and S6 phosphorylation. These latter observations
showing reversibility of the effects of iron depletion could not be attrib-
uted to changes in mTOR abundance, which was unaffected by modiﬁ-
cation of cellular iron status (Fig. 4B).
3.5. Modulation of REDD1 expression in Caco-2 cells in response to DFO
treatment
REDD1, a negative regulator ofmTORC1 signalling, is induced by var-
ious environmental stresses and its ectopic over-expression in HEK293
cells was recently shown to also induce a reduction in AktThr308 phos-
phorylation [16]. We therefore explored whether REDD1 may partici-
pate in the response to iron depletion observed in our cells. Fig. 5A
shows that REDD1 gene expression was elevated by over 5-fold in cells
treated with 100 μM DFO and that, over this same dose and incubation
period, the iron chelator increased REDD1 protein by ~3-fold (Fig. 5B).
This DFO-induced increase in REDD1 correlated with a loss in S6K1
and S6 phosphorylation and was repressed upon resupplementing
DFO-treated cells with iron in a time-dependent manner (Fig. 5C).
3.6. A role for PP2A in the regulation of REDD1 expression and mTORC1
signalling in iron-depleted cells
Previouswork has suggested that REDD1 can interact with PP2A and
inﬂuence mTORC1 signalling by inducing the dephosphorylation and
upstream inactivation of Akt on Thr308 [16]. Consistent with these pre-
vious observations immunoprecipitation of PP2Ac from Caco-2 cellsFig. 7.Effects ofDFO and proteosomal inhibition onREDD1expression andmTORC1 signalling in
to incubationwith 10 μMMG132, a proteasomal inhibitor for time periods indicated. At the end
native S6. Blots from a minimum of three experiments were quantiﬁed and the data presented
(*p b 0.05). (B) Caco-2 cells were pre-incubated in the absence or presence of 100 μM DFO for
Transferrin to resupplement iron to cells. In some experiments, cells were also coincubate
treatment period. Cells were lysed and immunoblotted for analysis of REDD1 and phosphoryl
and p70S6 Kinase Thr389 immunoblots were quantiﬁed (right bar graph panel) and data pre
differences (p b 0.05) between indicated bar values.revealed that we could detect coimmunoprecipitation of endogenous
REDD1 in DFO but not in control cells treated with vehicle solution
alone. The immunoreactive REDD1 band migrated marginally ahead of
the much more intense IgG light chain signal (Fig. 6A). Evidence in the
literature indicates that PP2A functions as a negative regulator of Akt
and that decreased Tyr307 phosphorylation of the catalytic PP2A subunit
(PP2Ac) is associated with increased phosphatase activity towards sub-
strates such as Akt [29–31]. In line with this idea, Fig. 6B shows that
PP2Ac Tyr307 phosphorylation was reduced in DFO-treated cells in a
dose and time-dependent manner and that AktThr308 phosphorylation
was accordingly reduced in DFO treated cells (Fig. 6C). The notion that
dephosphorylation of this Akt site is likelymediated by PP2A is support-
ed by our ﬁnding that it was suppressed by okadaic acid, a potent PP2A
inhibitor (IC50=0.1–1 nM[32]), in DFO-treated cells (Fig. 6C). To deter-
mine the likely impact of increased PP2A activity upon REDD1 and
mTORC1 signalling in DFO-treated cells we further explored the effect
of okadaic acid on this signalling axis. Fig. 6D shows that the DFO-
induced increase in REDD1 was dramatically attenuated when DFO-
treated cells were coincubated with okadaic acid. Under these circum-
stances, the loss in mTORC1 signalling associated with iron depletion
was also ameliorated as judged by analysis of S6K1 and S6 phosphory-
lation (Fig. 6D and E). Expression of the REDD1 gene can be upregulated
by a number of transcription factors, including HIF-1 [33] whose abun-
dance is known to be enhanced in iron-depleted tissues [34]. In line
with previousworkwe ﬁnd that iron depletion increases HIF1α content
in Caco-2 cells. However, whilst induction of REDD1 was sensitive to
okadaic acid the increase in HIF1α was not affected by the inhibitor
(Fig. 6E).3.7. Effects of modulating REDD1 protein on mTORC1 signalling in DFO-
treated cells
To assess the importance of REDD1 as a modulator of mTORC1 sig-
nalling in iron-depleted cells we subsequently investigated the impactCaco-2 cells. (A) Cellswere treated in the absence or presence of 100 μMDFO for 16 h prior
of these incubations cellswere lysed and immunoblottedwith antibodies against REDD1or
as mean ± SEM. The asterisk denotes signiﬁcant differences between the indicated values
having been treated with DFO for this period subsequently incubated with human holo-
d with 10 μM MG132 during the duration of the DFO or DFO with + holo-Transferin
ation of p70S6 Kinase Thr389, 4E-BP1 Ser65, total p70S6 Kinase, 4EBP-1 and actin. REDD1
sented as mean ± SEM from at least three experiments. The asterisks signify signiﬁcant
420 A. Watson et al. / Cellular Signalling 28 (2016) 412–424of either stabilising REDD1 or substantially reducing its transcriptional
expression. REDD1 is a target for the Cul4a-DDB1-ROC1-β-TRCP ubiqui-
tin E3 ligase complex [35] and can be degraded by the ubiquitin-
proteosome system [35]. In line with this, in addition to its induction
by DFO treatment, the cellular abundance of REDD1 was further en-
hanced in a time-dependent manner by cell treatment with MG132, a
proteosomal inhibitor (Fig. 7A). Proteosomal inhibition in the absence
of DFO treatment was also effective in stabilising REDD1 (Fig. 7B, com-
pare lane 1 with 4) suggesting that under normal circumstances the
low abundance of REDD1 most likely reﬂects its rapid turnover within
cells. Accumulating REDD1within cells through proteosomal inhibition
also serves to inhibit phosphorylation of S6K1 and 4E-BP1 (Fig. 7B,
compare Lanes 1 and 4). Intriguingly, whilst iron resupplementation
in DFO-treated cells antagonises REDD1 expression and the loss in
S6K1 and 4E-BP1 phosphorylation (Fig. 7B, compare Lanes 2 and 3),
this intervention fails to repress accumulation of REDD1 or subvert the
loss in mTORC1 signalling in cells incubated with MG132 (Fig. 7B, com-
pare Lanes 5 and 6).
In contrast to stabilising REDD1 protein, treatment of cells with acti-
nomycin D, a transcriptional inhibitor, induced a striking time-
dependent reduction in REDD1 protein in DFO-treated cells (Fig. 8A),
consistent with the known short half-life of this protein in cells [36,
37]. This decline in REDD1 expression correlated with a corresponding
increase in S6K1 phosphorylation despite cells being iron depleted.Fig. 8. Effects ofmodulating REDD1 expression onDFO-induced changes inmTORC1 signalling in
16 h prior to incubation with 100 μMActinomycin D, a transcriptional inhibitor for time period
antibodies against HIF-1α, REDD1, p70S6K Thr389, p70S6K and actin. REDD1 and p70S6K Thr389
three experiments. The asterisks signify signiﬁcant differences (p b 0.05) between indicated ba
siRNA or 1 μg REDD1 siRNA for 24 h were incubated in the absence or presence of 100 μMDFO
against REDD1, 4E-BP1 Ser65, 4E-BP1 and Actin. The blots are representative of two separate eThis latter response could not be attributed to changes in total S6K1
abundancewhichwe found to be unaffected over the actinomycin D in-
cubation period (Fig. 8A).Whilst REDD1 protein contentwas rapidly re-
duced by actinomycin D in iron depleted cells it is noteworthy that the
increased abundance of HIF1αwas sustained formuch longer periods in
the presence of the transcription inhibitor.
The changes in REDD1 abundance associatedwithMG132 or actino-
mycin D treatment shown in Figs. 7 and 8A inversely correlate with
what happens to mTORC1 signalling. For more direct evidence that
REDD1 is a key determinant of mTORC1 signalling in iron-depleted
cells we also monitored the effect of DFO treatment in Caco-2 cells
in which REDD1 had been transiently silenced. Fig. 8B shows that
16 h of DFO treatment induces a robust increase in REDD1 protein
in untransfected Caco-2 cells or those that had been transiently
transfected with a control siRNA, but that this induction was notably
muted in cells transfected with siRNA targeting REDD1. Whilst phos-
phorylation of 4E-BP1 was markedly reduced in the two iron-depleted
control groupswewere able to detect elevated 4E-BP1 phosphorylation
in DFO-treated REDD1 silenced cells.
3.8. Effects of DFO treatment on cellular protein synthesis
Impaired activation of the mTORC1/S6K1signalling pathway in iron
depleted cells would be expected to impact negatively on proteinCaco-2 cells. (A) Caco-2 cellswere incubated in the absence or presence of 100 μMDFO for
s indicated. At the end of these treatments cells were lysed and lysates immunblottedwith
abundance was quantiﬁed using ImageJ and data presented asmean± SEM from at least
r values. (B) Untransfected Caco-2 cells or those transiently transfected with 1 μg control
for 16 h. At the end of this treatment cells were lysed and immunoblotted with antibodies
xperiments.
Fig. 9. Effects of DFO-induced iron depletion upon protein synthesis in Caco-2 cells. Caco-2
cells were incubated with or without 100 μMDFO or 100 μM iron-loaded DFO for 16 h. In
some experiments, DFO-treated cells were also incubated with okadaic acid (OKA,
100 nmol/l) during the penultimate 2 h iron depletion period with DFO, whereas a sub-
set of non DFO-treated cells were incubated with 50 μg/ml of cycloheximide for 2 h. At
the end of these respective treatments with DFO, iron-loaded DFO, okadaic acid or
cycloheximide cells were incubated with 1 μM puromycin for 30 min before being lysed.
Cell lysates were immunoblotted with antibodies to puromycin, REDD1 and actin.
Quantiﬁcation of puromycylated proteins from each treatment is presented as mean ±
SEM from three independent experiments. Asterisks denote a signiﬁcant change
(*p b 0.05) from the value for DFO-treated cells (lane 2).
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puromycin antibody to assess incorporation of puromycin, a tyrosine-
tRNA mimetic, into newly synthesised proteins. Fig. 9 shows that we
were able to detect puromycylated proteins in cells held in normal
media (Lane 1), but their abundance was signiﬁcantly reduced in iron-
depleted cells (Lane 2). This decrease was not apparent in Caco-2 cells
that had been treated with iron loaded DFO (Lane 3) or those incubated
with DFO, but in the presence of okadaic acid (Lane 5)— circumstances
during which REDD1 expression was notably repressed (Fig. 9 lower
panel). As an internal control, we also observed no labelling of proteins
when Caco-2 cells were incubatedwith cycloheximide, which effective-
ly precludes the incorporation of puromycin into nascent proteins by
inhibiting translocation of mRNA on 80S ribosomes (Fig. 9, Lane 4).
These changes in protein synthesis are consistent with effects that
DFO has upon cellular growth and proliferation (Fig. 1).4. Discussion
The ﬁndings presented herein demonstrate that DFO-induced iron
depletion promotes a loss in mTORC1-directed signalling in human in-
testinal Caco-2 cells and that this is associated with a marked reduction
in protein synthetic capacity within these cells. Our data indicate that
these changes are most likely driven by an increase in the expression
of REDD1, a protein known to negatively regulate mTORC1 signalling
[17,38] and whose sustained upregulation in DFO-treated cells requires
protein phosphatase 2A (PP2A) activity. Importantly, we demonstrate
that PP2A inhibition or strategies that repress the increase in REDD1 ex-
pression alleviate the inhibition in mTORC1 signalling that is otherwise
seen in iron depleted cells (Fig. 10 summarises our current working
model of how iron deﬁciency impacts upon mTORC1 signalling).
Previous work using myeloid leukaemia cells identiﬁed REDD1 as
one of a number of genes upregulated in response to cell treatment
with the iron chelator, deferasirox [39]. The precise mechanism driving
REDD1 expression under these circumstances has remained unclear, al-
though given that iron chelators (such as DFO and deferasirox) can act
as hypoxiamimetics, it is plausible that increases in REDD1 gene expres-
sion form part of a cellular hypoxic stress response. A central and well
established feature of this response is the increased cellular abundance
of the hypoxia-inducible transcription factor (HIF) which orchestrates
expression of numerous target genes, including REDD1 [40,41]. Consis-
tent with this possibility, our analysis reveals that DFO treatment of
Caco-2 cells is associated with increases in HIF-1α content. Neverthe-
less, we ﬁnd that rates of cellular oxygen consumption and extracellular
acidiﬁcation (which reﬂect mitochondrial respiration and glycolytic ac-
tivity, respectively) are not signiﬁcantly altered in Caco-2 cells treated
with DFO for 16 h (data not shown), which would suggest that cells re-
tain normoxic status over the DFO treatment period used in our studies
and that the increase in HIF-1α is not a consequence of hypoxia per se. A
more likely explanation is that it arises through DFO-mediated inhibi-
tion of prolyl hydroxylases due to chelation of their Fe2+ cofactor [34].
These enzymes help direct HIF-1α for proteosomal degradation and in-
hibition of their enzymatic activitywill facilitate stabilisation/accumula-
tion of HIF-1α and transcription of its target genes. In any case, the
requirement for HIF-1α in mediating REDD1 gene expression in our
iron depleted cells remains equivocal as we can “uncouple” effects of
DFO on these two proteins with okadaic acid, which counters accumu-
lation of REDD1 but not HIF-1α. This ﬁnding would seemingly negate
a role for HIF-1 in the regulation of REDD1 expression in our DFO-
treated cells and would be consistent with previous work suggesting
that HIF-1 is neither necessary nor sufﬁcient for hypoxia-induced
downregulation of themTOR pathway [42]. Nevertheless, since okadaic
acid restrains the DFO-induced increase in REDD1mRNAwe cannot en-
tirely exclude the possibility that our ﬁndings may at least partly reﬂect
a requirement for PP2A to support DNA binding and/or transcriptional
activation of the REDD1 gene in DFO-treated cells by HIF-1 or other
known REDD1 transcription factors (e.g. ATF4, p53 and p63) [43,44].
Such a possibility is not unprecedented in light of recent work showing
that PP2A regulates binding of the sterol response element-binding pro-
tein (SREBP-2) to the sterol response element located within the pro-
moter of the LDL receptor gene [45].
The notion that PP2A is an important regulator of the REDD1/
mTORC1 signalling axis in iron depleted cells is supported by analysis
of its phosphorylation status.Whilst phosphorylation of the catalytic sub-
unit of PP2A on Tyr307 results in the inactivation of the enzyme [46], our
studies reveal, for the ﬁrst time, that DFO treatment of Caco-2 cells in-
duces a signiﬁcant reduction in phosphorylation of this site on PP2Ac.
Phosphorylation of Tyr307 is targeted by Src kinase,whose activitywas re-
cently shown to be inhibited in iron-depleted cells [24]. Consequently, re-
duced Tyr307 phosphorylation of PP2Ac would be expected to enhance
PP2A activity, which we suggest will have two important consequences
in the context of the studies reported herein. First, elevated PP2A activity
would support the DFO-induced increase in REDD1 gene expression
Fig. 10. Scheme illustrating the mechanism by which mTORC1 signalling is regulated by iron depletion in Caco-2 cells.
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which, in turn, will serve to inhibit mTORC1 signalling by maintaining
TSC2-mediated repression of Rheb. From a mechanistic stand point,
dephosphorylation of Akt depends upon the targeting of PP2A to Akt by
REDD1. This latter proposition is based on the ﬁnding that in cells ex-
pressing REDD1mutants that donot inhibitmTORC1 signalling the ability
to coprecipitate PP2Awith Akt and the loss in AktThr308 phosphorylation
that normally results from this association is markedly reduced [18].
Whether such a mechanism operates independently or in conjunction
with one in which REDD1 also promotes dissociation of TSC2 from inhib-
itory 14-3-3 proteins [17] to suppress mTORC1 signalling in our iron-
depleted cells is currently unknown. It should be stressed that there is
no direct evidence in support of direct REDD1/14-3-3 interactions and,
indeed, structure–function studies do not favour them [47]. However,
our ﬁndings clearly suggest that the cellular expression/abundance of
REDD1 is a key determinant of mTORC1 signalling capacity in iron-
depleted cells. This assertion is based upon the following lines of evi-
dence. First, the reduction in mTOR signalling in iron depleted cells can
be reversed upon resupplementing DFO-treated cells with iron, which
not only attenuates REDD1 gene transcription but promotes rapid loss
of REDD1 protein. Second, DFO-induced inhibition of mTORC1 is
antagonised in cells in which REDD1 gene expression is halted either by
use of a transcriptional inhibitor or REDD1 siRNA. Finally, since REDD1
is rapidly degraded by the proteasome, inhibiting proteosomal activity
withMG132 results in its cellular accumulation and a concomitant reduc-
tion in mTORC1 signalling. Moreover, it is noteworthy that inhibition of
mTOR signalling in DFO- or MG132-treated cells occurs despite the pres-
ence of amino acids and serum growth factors, thereby signifying that ac-
cumulation of REDD1 serves as a potent countermand that is capable of
over-riding the stimulatory input normally conveyed by nutrients and
growth factors upon mTORC1 [6].
Through its ability to phosphorylate its downstream effector mole-
cules, S6K1 and 4E-BP1, mTOR exerts a positive inﬂuence upon mRNA
translation. In line with this view, the loss in mTOR signalling that we
observe in iron-depleted cells is associated with a marked inhibitionin protein synthesis. This reduced protein synthetic drive is, we suggest,
linked to induction of REDD1 as it can be mitigated by okadaic
acid which suppresses REDD1 gene expression and thereby helps to
maintain mTORC1 activity. Chronic exposure of Caco-2 cells to DFO
also has a profound inhibitory effect on their growth and proliferative
capacity. However, whilst reduced cell proliferation would be in accord
with reduced protein synthesis anddata indicating thatmTORactivity is
required for supporting cell cycle transit through G2/M [48], it is impor-
tant to stress that growth inhibition of iron depleted cells is likely to
only be partly explained by inhibition of mTOR signalling. Reduced
iron availability will also inhibit the activity of ribonucleotide reductase
[49,50], an iron containing enzyme that crucially catalyses the forma-
tion of deoxyribonucleotides from ribonucleotides that are needed for
DNA synthesis/replication and hence cell division. Furthermore, previ-
ous global transcriptomic studies utilising microarray technology and
proteomic analyses of Caco-2 cells treated with DFO have reported sig-
niﬁcant changes in the expression of genes/proteins that fulﬁl essential
roles in metabolism, cell cycle activity and apoptosis that occur in a
manner that would serve to restrain growth and proliferation of iron-
depleted cells [51,52].
5. Conclusions
The present study shows that DFO-induced iron depletion prompts a
signiﬁcant increase in the expression of REDD1 that is associated with
reduced mTOR signalling to key end-points such as protein synthesis,
which, in turn, will impact negatively on cell growth and proliferation.
The ﬁndings have important implications from the perspective of man-
aging disorders linked to iron availability. They indicate that impaired
mTOR signalling may contribute to atrophy and resultant dysfunction
of the intestinal epithelium in individuals who are chronically iron
deﬁcient and therefore underscore the potential health beneﬁts
of dietary iron supplementation. The ﬁndings also signal the need to
carefully monitor the use and efﬁcacy of iron chelators. These com-
pounds have been used clinically to treat iron-overload conditions
423A. Watson et al. / Cellular Signalling 28 (2016) 412–424(e.g. haemochromatosis, thalassemia [53]) and, by limiting iron avail-
ability for DNA synthesis, may also be effective anti-neoplastic agents
that suppress growth and hyperproliferation of cancer cells [54]. How-
ever, our data would indicate that, unless iron chelators are used at con-
centrations that maintain iron stores within tight physiological limits or
offer selective toxicity towards cancer cells, theymay also inadvertently
compromise function of normal cells through their effect not just on the
mTOR pathway, but upon expression/activity of other proteinswith key
roles in signalling, metabolism and cell cycle biology.
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